FDMT Financials

Income Statement
MetricQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025
Revenue
3.0M
-96.4%
85.1M
+94444.4%
90.0K
+500.0%
15.0K
+7.1%
14.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
3.0M
-96.4%
85.1M
+94444.4%
90.0K
+500.0%
15.0K
+7.1%
14.0K
Operating Expenses
76.7M
+8.9%
70.4M
+14.9%
61.3M
+3.0%
59.5M
+10.9%
53.6M
R&D
65.0M
+12.8%
57.6M
+16.5%
49.4M
+3.1%
48.0M
+17.8%
40.7M
SG&A
11.7M
-8.5%
12.8M
+7.9%
11.8M
+2.8%
11.5M
-10.9%
12.9M
Operating Income
-73620000
-600.3%
14.7M
+124.1%
-61185000
-2.9%
-59456000
-10.9%
-53621000
EBITDA
-72351000
-554.2%
15.9M
+126.6%
-59924000
-2.8%
-58290000
-10.9%
-52570000
Net Income
-68760000
-454.5%
19.4M
+134.1%
-56876000
-4.1%
-54658000
-13.9%
-47972000
EPS (Basic)
$-1.01
-436.7%
$0.30
+129.7%
$-1.01
-3.1%
$-0.98
-14.0%
$-0.86
EPS (Diluted)
$-1.01
-436.7%
$0.30
+129.7%
$-1.01
-3.1%
$-0.98
-14.0%
$-0.86
Shares (Diluted)
68.1M
+6.5%
63.9M
+13.9%
56.1M
+0.4%
55.9M
+0.3%
55.7M
4D Molecular Therapeutics (FDMT) โ€” Financials